Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Zentalis Pharmaceuticals Inc.’s current trading price is -24.38% away from its 52-week high, while its distance from the 52-week low is 52.99%. The stock’s price range over this period has fluctuated between $15.55 and $31.46. The company, operating within the financial sector, had a trading volume of approximately 1.0 million for the day, which was noticeably higher than the average daily share volume of 0.57 million over the last 3 months.
Zentalis Pharmaceuticals Inc. (ZNTL) stock is currently valued at $23.79. During the last session, the stock experienced a remarkable rise, reaching $24.27 after opening at $24.26. The stock briefly dropped to $23.12 before ultimately closing at $24.25.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Zentalis Pharmaceuticals Inc. saw a rather unpredictable run in, in terms of market performance. The company’s stock reached its highest point at $31.46 on 05/30/23, while the lowest price for the same duration was marked at $15.55 on 03/10/23.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Zentalis Pharmaceuticals Inc. (ZNTL) has experienced a quarterly decline of -3.41% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.66B and boasts a workforce of 156 employees.
Zentalis Pharmaceuticals Inc.: What Analysts Are Saying
As of right now, 10 analysts are rating Zentalis Pharmaceuticals Inc. as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 25.90, with a change in price of +2.79. Similarly, Zentalis Pharmaceuticals Inc. recorded 774,309 in trading volume during the last 100 days, posting a change of +13.29%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for ZNTL stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
ZNTL Stock Stochastic Average
Today’s raw stochastic average for Zentalis Pharmaceuticals Inc. over the last 50 days is 11.34%.This indicates a decrease from the raw stochastic average of the past 20 days, which was 15.26%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 8.53% and 8.58%, respectively.
ZNTL Stock Price Performance Analysis
The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. Until today this year the stock’s price performance recorded an increase of 18.12%. However, over the last six months, the performance has been weaker by 30.21%. The price of ZNTL decreased -13.93% over the last 30 days. And in the last five days, it has fallen by -4.99%.
